In this article, the authors would like to apologize for an error inadvertently introduced into the paper. During pre-marketing clinical studies, reactions that presented with signs and symptoms consistent with olanzapine overdose were reported in patients following an injection of olanzapine pamoate. These reactions occurred in o0.1% of the injections and in approximately 2% of patients, according to the EU SPC, for olanzapine pamoate.
1,2 In the EU SPC, at the moment the manuscript was written, post-injection delirium syndrome (PDSS) occurred in approximately 1% of patients. In the introduction section on page 2, we inadvertently stated that PDSS occurred after about 1% of olanzapine pamoate injections (Citrome, 2009 
